Compare OPBK & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | VYGR |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.9M | 203.6M |
| IPO Year | 2018 | 2015 |
| Metric | OPBK | VYGR |
|---|---|---|
| Price | $14.74 | $3.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | $16.50 |
| AVG Volume (30 Days) | 57.8K | ★ 701.2K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | $3,204,000.00 | ★ $10,135,000.00 |
| Revenue This Year | $16.07 | $34.04 |
| Revenue Next Year | $11.60 | $7.92 |
| P/E Ratio | $30.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $2.88 |
| 52 Week High | $15.73 | $5.55 |
| Indicator | OPBK | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 43.22 |
| Support Level | $13.68 | $3.33 |
| Resistance Level | $15.07 | $4.33 |
| Average True Range (ATR) | 0.42 | 0.18 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 40.12 | 12.24 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.